Home > News > Abraxis BioScience splits in two
July 5th, 2007
Abraxis BioScience splits in two
Abstract:
The new Abraxis BioScience would become a more highly focused biotechnology company, which would concentrate more on the nab (nanoparticle-albumin bound) technology platform to deliver therapeutics, such as ABRAXANE (albumin-bound paclitaxel), and work towards new and personalized treatments to patients with life-threatening diseases, Soon-Shiong said.
Source:
biopharma-reporter.com
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||